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A Ab bs st tr ra ac ct t
The purpose of this article is to review basic research as well as clinical studies on Chinese hereditary colorectal
cancer. Hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) accounts for 2.2% of all colorectal
cancer, and Chinese criteria for suspected HNPCC have been developed. Germline mutations as well as large
genomic rearrangements of mismatch repair (MMR) genes are responsible for this syndrome. Gastric cancer is the
second most common cancer in Chinese HNPCC patients. Contrary to sporadic colorectal cancer in the Chinese
population, HNPCC does not typically present with rectal cancer. Incidence of familial adenomatous polyposis
(FAP) in China is approximately 1.5/100,000. Polyps in Chinese FAP patients can emerge as early as 16 months
old, but malignant transformation usually occurs in the third and fourth decade. Total resection of the colon and
rectum is necessary in FAP patients. For unresectable duodenal polyps, chemopreventive agents may be used. 
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I In nt tr ro od du uc ct ti io on n
According to the IACR (International Association of
Cancer Registries) [1], in the year 2002, 150,956 new
cases of colorectal cancer (CRC) were expected to occur
in China, while the age-standardised incidence of
colorectal cancer would be 13.6/100,000 in men and
9.3/100,000 in women. These predictions were derived
from cancer statistics of six separate areas in China from
1993 to 1997. However, in 1999 colorectal cancer
incidence in Shanghai, the biggest city in China included
in  the  IARC’s  estimates,  had  already  reached
16.2/100,000 in men and 14.5/100,000 in women
[2], more than a one-fold increase compared with the
1972-1974 period [3]. Shanghai has witnessed the
highest and fastest growing colorectal cancer incidence
in China. It is a fact that the incidence of colorectal
cancer in China is increasing rapidly. 
Genetic  alterations  as  well  as  environmental
influences are thought to underlie the development of
all colorectal malignancies. In general, environmental
changes play a critical role in the rapid growth of
colorectal cancer incidence, while the contribution of
genetic alterations that cause hereditary colorectal
cancer is probably relatively stable. Although there are
no statistics available on the incidence of hereditary
colorectal cancer in China as a whole, we expect that
the incidence of hereditary colorectal cancer in China
is growing due to the changing environment as well as
to more diagnosed cases because of more clearly
specified diagnostic criteria. According to Lynch et al.H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2005; 3(4) 156
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[4], approximately 20% of all patients with colorectal
cancer carry a familial risk, with 5-10% inherited as
a Mendelian trait. Hereditary colorectal cancer can be
broadly classified into two categories based on the
presence or absence of multiple colorectal polyps:
polyposis syndromes and nonpolyposis syndromes. The
former can be further divided on the basis of histologic
criteria into adenomatous-like FAP and hamartomatous
syndromes like juvenile polyposis and Peutz-Jeghers
syndrome. This article will review clinical and basic
research on both types of hereditary colorectal cancer
syndromes in China, focusing on the differences with
Western countries and particular characteristics of
Chinese hereditary colorectal cancer. Relevant new
issues on hereditary colorectal cancer outside China
will also be discussed. 
H He er re ed di it ta ar ry y   n no on np po ol ly yp po os si is s   c co ol lo or re ec ct ta al l   
c ca an nc ce er r   ( (H HN NP PC CC C) )   
HNPCC, which some prefer to refer to as Lynch
syndrome, is an autosomal dominant inherited cancer
syndrome caused by germline mutations of mismatch
repair (MMR) genes. This disorder is characterised by
early onset of colorectal cancer and other malignancies
including gastric, endometrial, ovarian, ureter, renal
pelvis, hepatobiliary tract and small bowel cancer.
When the name Lynch syndrome was first coined by
Borland in 1984 [5], a Lynch family with five cases was
reported in the same year in a Chinese medical journal
[6], but it was not until 1998 that a series of Chinese
HNPCC families began to be studied [7]. Several
research groups in China have been devoted to
collecting and studying Chinese Lynch families. With
their effort, clinical and molecular research on HNPCCs
in China has been greatly accelerated. 
C Cl li in ni ic ca al l   d di ia ag gn no os si is s
The diagnostic criteria for HNPCC continue to evolve
as  the  understanding  and  characteristics  of  this
heterogeneous  disorder  improve.  The  Amsterdam
criteria, which were established in 1990 and revised in
1999, have been the classical diagnostic criteria of
HNPCC. Based on the Amsterdam criteria, HNPCC in
China accounts for 2.2% of all colorectal cancer [8].
However, the Amsterdam criteria are too strict for
diagnostic purposes or for exclusion of patients from
further work-up. More importantly, they do not account
for patients from small families, which is a common
phenomenon in China. With these deficiencies in mind,
several sets of modified clinical criteria such as the
Bethesda criteria [9], revised Bethesda criteria [10],
Japanese criteria [11] and Korean suspected criteria [12]
have been proposed. The National Hereditary Colorectal
Cancer Network of China proposed Chinese HNPCC
criteria in 2003 [13]. Based on the Korean suspected
criteria, Chinese HNPCC criteria have been modified
as follows: at least two pathologically verified colorectal
cancers in a family; at least two of them are first-degree
relatives including parents or siblings; in addition, at least
one of these conditions has to be satisfied: (1) at least
one case develops multiple colorectal cancer, including
adenomas,  (2)  at  least  one  colorectal  cancer  is
diagnosed before age 50, (3) at least one case with
extracolonic malignancies including gastric, endometrial,
small bowel, ureter and renal pelvis, ovarian, and
hepatobiliary malignancies. The differences between
Chinese criteria and other criteria are listed in Table 1. 
G Ge en ne et ti ic cs s
Since the discovery of the major human gene with
DNA misrepair function in 1993-1995, mutations in
MSH2, MLH1, MSH6 and PMS2 have been convincingly
associated with HNPCC. According to the database
maintained by the international collaborative group on
HNPCC  (International  Society  for  Gastrointestinal
Hereditary Tumor, InSiGHT), approximately 450 different
HNPCC-associated mismatch repair gene mutations are
known that primarily involve MLH1 (~50%), MSH2
(~39%), and MSH6 (~7%) [14]. Most of these mutations
are  frameshift  and  nonsense  mutations  which  are
obviously pathogenic, but the roles missense mutations
play are diversified. Some may be harmless single
nucleotide polymorphisms, whereas others may contribute
to cancer risks. Studying segregation of these mutations
in affected and unaffected relatives, and functional assays,
are among the methods to investigate the functional
nature of these missense mutations. In addition to these
point mutations, large genomic rearrangements of MMR
genes have recently been reported to play an important
role in the development of HNPCC. A systematic search
of 439 HNPCC families for genomic rearrangements in
MSH2, MLH1, MSH6 and PMS2 has identified 48
genomic rearrangements in 68 unrelated kindreds.
Twenty-nine out of 48 were found in MSH2, 13 in MLH1,
2in MSH6, and 4 in PMS2  [15]. 
For the purpose of presenting the genetic alterations
in Chinese HNPCC families, eight doctorate studies
[16-23] which aimed at germline mutation detection
in Chinese HNPCC have been summarised. A total of
35 clinically diagnosed unrelated HNPCC families,
most of them meeting Amsterdam criteria, have beenH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2005; 3(4) 157
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T Ta ab bl le e   1 1. .   Comparison of clinical diagnostic criteria for HNPCC
C Cr ri it te er ri ia a   I It te em ms s A Am ms st te er rd da am m   c cr ri it te er ri ia a J Ja ap pa an ne es se e    C Ch hi in ne es se e   c cr ri it te er ri ia a J Ja ap pa an ne es se e    B Be et th he es sd da a   
( (i in nc cl lu ud di in ng g   I I   a an nd d   I II I   ) ) c cr ri it te er ri ia a   A A c cr ri it te er ri ia a   B B g gu ui id de el li in ne es s   ( (2 20 00 04 4) )
c co ol lo or re ec ct ta al l    ≥≥ 3 3   ( (i in nc cl lu ud di in ng g    ≥≥ 3 3 ≥≥ 2 2    ≥≥ 2 2    ≥≥ 1 1
c ca an nc ce er r   p pa at ti ie en nt ts s e ex xt tr ra ac co ol lo on ni ic c   t tu um mo ou ur rs s) )
first-degree  at least 2 pairs at least 2 pairs at least 1 pair at least 1 pair no request
relatives
generations  at least 2 successive  no request  no request no request no request
affected generations
exclude FAP yes no request no request no request no request
with any of these: at least 1 should be  no request at least 1 should   at least 1 should   CRC diagnosed 
diagnosed before  be diagnosed be diagnosed before age 50
age 50 before age 50 before age 50
multiple colorectal multiple colorectal Multiple colorectal
tumors (including  cancers tumors
adenomas)
extracolorectal  extracolorectal HNPCC-associated
cancer cancer tumours 
right colon MSI-H pathologic
involvement associated features 
in a colorectal cancer 
diagnosed before age 60
– one with colorectal cancer
– one or more first 
– or second-degree relatives
with HNPCC-related tumour
– one of the cancers being
diagnosed before age 50
– one with colorectal cancer 
– two or more first 
– or second-degree relatives
with HNPCC-related tumour
Note: MSI-H pathologic associated features including the presence of tumor infiltrating lymphocytes, Crohn's-like lymphocytic reaction, mucinous/signet-ring 
differentiation, or medullary growth pattern
found to carry 43 germline mutations (60% MLH1
mutations and 40% MSH2 mutations (Table 2). All of
the genomic sites of mutations were verified by DNA
sequencing. Among these mutations, 10/43 (23%)
result in a shift of transcribe reading frame. Eight out
of forty-three (19%) are nonsense mutations which lead
to truncating proteins. These are obviously pathological
mutations. However, missense and splice site mutations,
which account for 14/43 (33%) and 7/43 (16%),
respectively, are putative mutations needing further
pathological  verifications.  Four  of  the  observed
mutations were small nucleotide deletions, which may
help in discovering the critical amino acid related
functions  of  MMR  proteins.  In  addition  to  small
mutations, large genomic rearrangements of Chinese
HNPCC are also investigated. Huang et al. first
reported a genomic deletion ranging from exon 1 to
exon 7 of MSH2 gene in a Chinese HNPCC family
meeting Amsterdam criteria [24]. A recent study [25]
shows that large genomic rearrangements, mostly
deletions rather than duplications, were responsible for
7 out of 45 hereditary colorectal patients. These large
fragment aberrations, uncovered in both MSH2 and
MLH1, indicate that large genomic rearrangements
play a role in the pathogenesis of Chinese hereditary
CRC patients. So far, the genetic alterations in Chinese
HNPCC appear similar to those in Western countries;
however, there are no data yet on the prevalence of
Chinese MSH6 and PMS2 gene mutations. 
In the Chinese studies, colorectal cancer patients were
selected for germline mutation detection, more frequentlyH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2005; 3(4) 158
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T Ta ab bl le e   2 2. .   Germline MLH1 and MSH2 mutations observed in Chinese HNPCC families
F Fa am mi il ly y C Cr ri it te er ri ia a m mu ut ta at ti io on n   i in n: : m mu ut ta at ti io on n   t ty yp pe e    r re ef fe er re en nc ce e
M ML LH H1 1 M MS SH H2 2   
C4 Amsterdam E18 c.2081 int T E15 c.2469 int C  frameshift [16]
c.2471 int G  frameshift
c. 2578 int T frameshift
C11 Amsterdam E13 c.2091 T>A nonsense [16]
C13 Amsterdam E11 c.1760int T frameshift [16]
c.1688 A>C  missense
H2Amsterdam E13 c.2 038 C>T nonsense [17]
H4  Amsterdam E2 c.199 A>G missense [18]
H9 Amsterdam E11 c.305 del 24bp small deletion [17]
H11 Amsterdam E1 c.14 A>C missense [17]
H27 Amsterdam E3 c.617 int A frameshift [17]
N8 Amsterdam E8 c.655 A>G missense [19]
N11 Amsterdam E3 c.265 G>T nonsense [19]
N14 Amsterdam E6 c.545+3 A>G splice point [19]
N23 Amsterdam E3 c.610 G>T nonsense [19]
N25 Amsterdam E8 c.677 G>A missense [19]
HW7 Amsterdam E14 c.2228 C>A nonsense [20]
HW5 Amsterdam E14 c.1588-1590 del small deletion [20]
C1  Japan E11 c.934 int A frameshift [21]
C6 Japan E1 c.21 G>C missense [22]
C8 Japan E12 c.1198 C>G missense [21]
c.1261 C>G missense
c.1364 int C frameshift
c.1372 int C frameshift
N18 Japan E9 c.790+1 G>A splice point [19]
N26 Japan E14 c.2211-2 A>C splice point [19]
HW6 Japan E15 c.1731+1 A>G missense [20]
H12China  E15 c.2 516 G>A  missense [18]
H20 China E19 c.2250 G>C  nonsense [18]
H5  *  E3 c.425 G>C  nonsense [23]
H6 * E15 c.1731 G>A splice point [23]
H17 * E15 c.1731 G>A splice point [23]
H45 * E16 c.1846 del AAG small deletion [23]
H47 * E12 c.1151 T>A  missense [23]
H52*  E2  c.194 G>A missense [2 3]
H56 * E16 c.2792 A>C  missense [23]
H62* E14 c.1588 del TTC small deletion [2 3]
H64 * E15 c.1731+1 G>A splice point [23]
H65 * E14 c.2228 C>A  nonsense [23]
H67 * E14 c.1559-2 G>A splice point [23]
H68 * E2 c.137 G>T missense [23]
E11 c.914 int 24  frameshift [23]
E=exon, c=codon 
* = clinical diagnostic criteria for each of these families are unknown, but it is clear that one of them meets the Bethesda criteria and three of them meet the
Japanese criteriaH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2005; 3(4) 159
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using criteria for suspected HNPCC rather than the
Bethesda criteria. Table 3 shows different detection rates
of germline mutations in typical and suspected HNPCC
families. The highest rate was observed in kindreds
meeting the Amsterdam criteria, which is about 44%,
similar to that in reports from Western countries, which
often quote a rate between 40% and 60%. Compared
with the Bethesda criteria, we prefer to use the suspected
HNPCC criteria in the clinical setting of screening for
HNPCC. Especially in small Chinese families we would
suggest using the suspected HNPCC criteria rather than
the Amsterdam criteria. 
C Cl li in ni ic ca al l   m ma an ni if fe es st ta at ti io on ns s
The  most  striking  feature  of  HNPCC  is  the
predisposition for early onset and/or multiple colorectal
malignancies. The mean age of onset of colorectal
cancer is 44 years, approximately 20 years earlier than
that for sporadic colorectal cancer. In Lynch families,
colorectal  cancer  tends  to  be  multiple,  either
synchronously (18%) or metachronously (24%) [26].
Other features of HNPCC involve proximal location of
CRC, mucinous or poorly differentiated histology, and
better prognosis. Previous studies [16, 27-48] have
shown features of colorectal cancer in Chinese HNPCC
patients (Table 4). With a few exceptions, clinical
manifestations of Chinese HNPCC colorectal cancer are
largely the same as those described above. However,
the involvement of rectal cancer in HNPCC is the most
interesting exception. Contrary to sporadic CRC in the
Western world, more than half of colorectal cancer in
China is rectal cancer rather than colon cancer. But this
distribution does not exist in colorectal cancer in HNPCC
families. Although they account for less than half of all
cases of colorectal cancer, rectal cancer in Lynch families
is considerably reduced compared with sporadic CRCs.
This may indicate differences in oncogenetic pathways
between HNPCC and sporadic CRCs. 
Lynch syndrome is associated with a wide spectrum
of cancers. The pattern of cancers has changed over time.
Previous studies [49] indicate that there are several ways
to verify whether or not a particular tumour may be
associated with HNPCC. A demonstrated increase in risk
of developing a particular tumour type in HNPCC families
(or better, proven mutation carriers) is the classical
approach taken. Based on these principles, the recent
Bethesda conference advised that colorectal, endometrial,
gastric, ovarian, small bowel, hepatobiliary, ureter and
renal pelvis cancer should be included in the HNPCC-
associated tumour spectrum [10]. However, the tumour
spectrum of HNPCC families from Western countries is
quite different to that from the Far East. This reflects the
variation in incidence of cancers in the respective
populations. For example, gastric cancer instead of
endometrial cancer is the second most common cancer
in  Chinese  Lynch  syndrome  families.  Among  30
Amsterdam  families,  10  out  of  27  extracolonic
malignancies involved gastric cancer, much more than
the 4 cases of endometrial cancer [50]. Because no
difference in clinical manifestation between HNPCC-
associated gastric cancer and familial gastric cancer has
been found [51], further studies of germline mutations of
HNPCC-associated gastric cancer are needed. 
M Ma an na ag ge em me en nt t   a an nd d   s su ur rv ve ei il ll la an nc ce e   
Identification of families with HNPCC syndrome
based  on  exact  clinical  information  is  inefficient
according to the genetic definition of HNPCC. Even
when the original Amsterdam criteria are met in
a family,  the  likelihood  of  detecting  a germline
mismatch repair gene mutation is only 40-60% [52].
However, one of the main benefits of genetic analysis
is  the  identification  of  mutation  negative  family
members in a positive pedigree, since it frees the
individual from anxiety and unnecessarily frequent
surveillance. An algorithm (Fig. 1) for the genetic
screening of individuals suspected for HNPCC has
been established by the National Hereditary Colorectal
Cancer Network of China [13]. Microsatellite instability
(MSI) and immunohistochemistry (IHC) testing for MMR
T Ta ab bl le e   3 3. .   Rates of detected germline MLH1 and MSH2 mutations in Chinese typical and suspected HNPCC patients
C Cl li in ni ic ca al l   C Cr ri it te er ri ia a p po os si it ti iv ve e/ /s sc cr re ee en ne ed d    p pe er rc ce en nt ta ag ge e r re ef fe er re en nc ce e
Amsterdam 23/52  44%  [ [1 18 8, ,   1 19 9, ,   2 20 0, ,   2 22 2, ,   2 23 3] ]
Japan 8/24 33%  [ [1 19 9, ,   2 20 0, ,   2 22 2] ]
Korea/China  5/23  22%  [18]*
Bethesda  1/19  5% [22]
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genes in tumour tissue is used as a complementary
screening method. Individuals with negative results are
excluded from further genetic testing. 
Once suspected HNPCC has been diagnosed, 
7-10  ml  of  peripheral  blood  of  the  patient  are
collected. 3 ml of this sample are used for white blood
cell immortalization, and the rest is stored in a -20°C
refrigerator for further study. Subsequently, clinical
screening takes place, including detailed endoscopic
examination of the whole gastrointestinal tract, followed
by ultrasound screening of the pelvis and hepatobiliary
organs. A regular surgical operation is performed if
a tumour is detected. Although multiple malignancies
in the colon and rectum are not infrequent in HNPCC,
prophylactic colectomy is still not recommended.
Recent studies [53] show that HNPCC colorectal
cancers, which are usually microsatellite intsable, are
insensitive to 5-FU-based chemotherapic regimens;
however, adjuvant chemotherapy after colonectomy is
still routinely prescribed. 
For patients with cancer or affect individuals with
a definitive inherited mutation, interval surveillance is
recommended for colorectal, gastric and endometrial
cancer. Data have shown [54] that lifetime risks for
colorectal, gastric and endometrial cancer in Chinese
HNPCC are 93.3%, 28.1% and 23.3% respectively.
Although these cancer risks might be overestimated,
surveillance  for  these  malignancies  is  necessary.
Considering the early onset of HNPCC malignancies
and the tendency for proximal and metachronous
colon lesions, full colonoscopy is recommended every
one to two years beginning between the ages of 20
and 25. Removal of polyps can also be undertaken
during endoscopic examination, which likely reduces
the risk of colorectal cancer and may prolong survival.
Other reasonable approaches involve transvaginal
ultrasound or endometrial aspiration with cytology to
screen for endometrial cancer and gastroendoscopy
for gastric cancer, based on available evidence and
expert opinions. 
F Fa am mi il li ia al l   a ad de en no om ma at to ou us s   p po ol ly yp po os si is s   ( (F FA AP P) )   
FAP is an autosomal dominantly inherited disease
with almost 100% penetrance characterised by the
presence  of  hundreds  to  thousands  of  small
adenomatous polyps, which if left untreated would almost
certainly develop into colorectal cancer. Mutations in the
adenomatous polyposis coli (APC) gene are responsible
for the syndrome. In addition, several variants of the
syndrome exist, namely Gardner syndrome, Turcot
T Ta ab bl le e   4 4. . Features of colorectal cancer In Chinese HNPCC and sporadic CRC patients
A Am ms st te er rd da am m   c cr ri it te er ri ia a    J Ja ap pa an ne es se e   c cr ri it te er ri ia a C Ch hi in ne es se e/ /K Ko or re ea an n   c cr ri it te er ri ia a S Sp po or ra ad di ic c   C CR RC C
c ca as se es s   ( (% %) ) c ca as se es s   ( (% %) ) c ca as se es s   ( (% %) ) c ca as se es s   ( (% %) )   
1 1. .   G Ge en nd de er r
m ma al le e 166 (55) 53 (48) 14 (33) 437 (47) 
f fe em ma al le e 136 (45) 57 (52) 28 (67) 50 (53) 
2 2. .   L Lo oc ca at ti io on n
r ri ig gh ht t   c co ol lo on n 85 (40) 33 (26) 144 (10) 
o ot th he er r   c co ol lo on n 155 (73) 65 (52)  26 (62) 540 (39) 
r re ec ct tu um m 57 (27)  60 (48) 16 (38) 853 (61) 
3 3. .   D Du uk ke e’ ’s s   s st ta ag ge e
A A& &B B 67 (63) 42 (46) 34 (81) 387 (49) 
C C& &D D    40 (37) 49 (54) 8 (19) 400 (51) 
4 4. .   D Di if ff fe er re en nt ti ia at ti io on n
l lo ow w   g gr ra ad de e 17 (40) 24 (39) 5 (13) 108 (14) 
h hi ig gh h   g gr ra ad de e 25 (50) 38 (61) 34 (87) 664 (86) 
5 5. .   M Mu ul lt ti ip pl le e   m ma al li ig gn na an nc cy y
t to ot ta al l 25 (9) 19 (15) 6 (14) 25 (3) 
s sy yn nc ch hr ro on no ou us s 5 (2) 11 (9) 
m me et ta ac ch hr ro on no ou us s 20 (7) 8 (6) 
n no ot t   m mu ul lt ti ip pl le e 260 (91) 110 (85) 36 (86) 867 (97) 
6 6. .   A Ad de en no om ma as s
w wi it th h   a ad de en no om ma as s 13 (18) 6 (21) 98 (18) 
w wi it th ho ou ut t   a ad de en no om ma as s 58 (82) 23 (79) 450 (82) H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2005; 3(4) 161
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syndrome and attenuated adenomatous polyposis (AAPC
or AFAP). Compared with HNPCC, fewer research papers
have been published on FAP in China. 
I In nc ci id de en nc ce e
In China, of all colorectal cancer, only 0.94% is
due to FAP . According to a survey executed twenty years
age in a county in the south-east of China, the
incidence of FAP in 18,950 individuals above age 30
was estimated to be approximately 1.5/100,000 [55].
However, this was an outcome after screening by 15cm
rectum endoscopy; therefore the real incidence in this
county would probably be a little higher. 
C Cl li in ni ic ca al l   f fe ea at tu ur re es s
The hallmark of FAP is the growth of profuse
adenomatous colorectal polyps at a young age.
Diarrhoea, gastrointestinal bleeding and abdominal
pain caused by polyps lead to the diagnosis. The polyps
in FAP have a slight predisposition for the distal colon.
However, the most important feature in Chinese FAP is
the incidence of rectum polyps. Among 42 FAP patients
in their first visit to the hospital, 30 were found to have
polyps in rectums simply by anal and rectum check by
finger, which finally led to the diagnosis of FAP [56].
Polyps can emerge in FAP patients as young as 16
months in China [57]. The number and size of these
polyps increases with time, ultimately reaching the
number of hundreds to thousands. If left untreated,
nearly all patients with this disorder will ultimately
develop colorectal cancer due to the vast number of
polyps. Liu Jian et al. [55]collected 50 FAP families in
the 1979-1993 period. FAP was diagnosed at the
average age of 31 years. Sixty-four percent of the
patients  had  developed  colorectal  cancer.  After
endoscopic screening of 57 first-degree relatives, another
18 FAP patients, with an average age of 19 years were
uncovered. Only 5.65% of these new-found FAP cases
had developed colorectal cancer, significantly lower than
that of the index cases. This shows that cancer risk for
Chinese FAP increases rapidly in the course of time,
especially during the third and fourth decades of life. As
in Western populations, age is the determinant of cancer
risk in Chinese FAP patients as well. 
A AP PC C   g ge en ne e   m mu ut ta at ti io on n   
Mutations in the APC gene are responsible for this
syndrome. In most cases, one allele with the mutated
gene is inherited from an affected parent. An acquired
(somatic) mutation in the other APC allele results in the
development of adenomas. However, a lack of family
history can be observed in one third of cases, which is
explained by de novo germline mutations. It has been
reported that an APC gene mutation can be detected
in 80-90% of FAP patients [58]. Gan Yuebo et al. [59]
first reported an APC germline mutation in Chinese
FAP patients in 1994. One out of 7 APC families was
found to have an AAAGA nucleotide deletion in codon
1309-1311. Recently, studies on the large exon 15 of
APC were reported. Five out of 22 FAP pedigrees were
found to have germline mutations in this exon, all them
being frameshift mutations [60]. Another study reported
6 out of 18 FAP patients having germline mutations on
4 fragments in exon 14 and 15 [61]. Recently, germline
mutations in the MYH gene have been identified as
another cause of adenomatous polyposis. The role of
MYH in Chinese (A) FAP has not been studied yet. 
M Ma an na ag ge em me en nt t   a an nd d   p pr re ev ve en nt ti io on n
After the clinical diagnosis of FAP , prophylactic
colostomy is recommended. However, the optimal
timing for this procedure is difficult to specify. The
balance  between  disease  progression  and  the
adolescent’s physical and psychosocial maturity should
be considered. Presently, the surgical methods in China
involve total resection of the colon and rectum with
permanent ileostomy, ileorectal anastomosis, ileal
pouch-anal anastomosis, subtotal colectomy plus rectal
polyposis  electrocautery  and  anastomosis  of  the
caecum and anus preserving the ileocecal valve [56,
57, 62]. However, no significant prevalence differences
have been observed among these methods, because
surgical outcomes depend on the skill of the surgeon
and the appropriateness of the surgical method rather
than personal preference. 
F Fi ig g. .   1 1. .   Genetic Screening Strategy for HNPCC in China
Germline mutation detection of hMSH2 and hMLH1
Families meeting Chinese criteria
positive negative negative positive
ICH MSI
Free from genetic analysisH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2005; 3(4) 162
Patients with FAP also develop adenomatous polyps
in  the  upper  gastrointestinal  tract.  Duodenal  and
ampullary polyps pose obstacles for treatment due to
surgical risks. The anti-COX2 agent celexib was recently
reported to have successfully prevented development of
upper gastrointestinal tract polyps in two Chinese FAP
patients [63]. A male and a female, both 20 years old,
both with germline APC gene mutations, each had 15-
41 polyps in their duodenal tract. After administration
of celexib 400 mg twice per day for 12-24 months, the
numbers of duodenal polyps decreased to 0-3. After
electrocautery removal of the remaining polyps, both
patients are free from duodenal polyps. Nonetheless,
a tricky thing in these cases is the effect of anti-COX2
agent on colorectal rather than duodenal polyps,
because no significant improvement has been observed
in colorectal polyps in both cases. Another strategy, using
sulindac to prevent the development of polyps, was used
in 18 Chinese FAP cases [64]. Although both a reduction
of numbers and an improvement of histopathology are
observed in colorectal polyps after 12 months of
administration, the difficulty remains that usually 3-6
months after stopping the administration of the drug
polyps recur. A similar result was reported in Western
countries. The chemopreventive effects of both NSAID
and anti-COX2 agents on FAP still need further study. 
H Ha am ma ar rt to om ma at to ou us s   p po ol ly yp po os si is s   s sy yn nd dr ro om me es s   
Hamatomatous polyposis in the gastrointestinal tract
mainly includes juvenile polyposis and Peutz-Jeghers
syndrome (PJS). Few reports can be found on Chinese
juvenile polyposis, but Peutz-Jeghers syndrome does not
seem to be very rare in the Chinese population. A clinical
analysis for 165 typical Chinese Peutz-Jeghers cases,
which were collected over the past 10 years, was reported
last year [65]. It was found that hamartomatous polyps
of the gastrointestinal tract and freckling of the lips and
buccal mucosa were the two main features of Chinese
PJS. Abdominal pain and gastrointestinal bleeding were
the main presentations and 58.7% of patients with
abdominal  pain  suffered  from  acute  intestinal
obstructions. Hamartomatous polyposis is associated with
a significantly increased cancer risk. In this report, 33
patients (20%) developed cancer, including 14 cases of
colorectal cancer, 5 of gastric cancer and 3 of small
bowel and cervix cancer. Cancers often developed at an
early age and tended to be of low differentiation. 
C Co on nc cl lu us si io on n
More  and  more  papers  on  Chinese  hereditary
colorectal cancer are being published. Genetic patterns,
clinical manifestations and management of Chinese
hereditary colorectal cancer have been studied. HNPCC
in the Chinese population, using national criteria for
suspected HNPCC, appears to have a similar genetic
background when compared with HNPCC in Western
countries. However, a different tumour spectrum has been
observed. Gastric cancer instead of endometrial cancer
is the second most common cancer in Chinese HNPCC.
Although rectal cancer is the major manifestation of
sporadic colorectal cancer in China, no such preference
has been observed in Chinese HNPCC patients. This
suggests differences in gene-environment interaction
between the two groups, which need to be further
explored. The genetic background of Chinese familial
adenomatous polyposis is less clear, but the management
and preventative strategies of FAP are more accessible.
Insight into the genetic and clinical features of both types
of hereditary colorectal cancer in the Chinese population
will help to prevent and manage these disorders. 
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